Ironwood Pharmaceuticals, Inc.

Microbia, Inc.

Whitehead Institute for Biomedical Research

G Todd Milne

Mark G Currie

Thea Norman

Shalina Mahajan-Miklos

Angelika Fretzen

John Jeffrey Talley

Joshua Trueheart

Brian Cali

Amir Sherman

Li Jing Sun

Craig N Zimmerman

Barbara B Chen

Kevin Sprott

Ara Mermerian

Timothy Claude Barden

James Philip Pearson

Charles Kim

Jane Yang

Yueh-Tyng Chien

Shannon Roberts

Jeffrey Cruz Silva

Gerald R Fink

John C Royer

Douglas A Holtzman

Kevin T Madden

Daniel P Zimmer

Caroline Kurtz

Wilmin Bartolini

Wayne Schairer

Regina Lundigran

Jing Jing Yang

Lixin Zhang

Regina Lundrigan

Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

Indole compounds

Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.

Methods and compositions for the treatment of heart failure and other disorders

The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

Methods and compositions for the treatment of gastrointestinal disorders

The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

Indoles that have activity as inhibitors of FAAH are described as are indoles and indole derivatives that have activity as inhibitors of DAO.

Useful indole compounds

The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

Modulators of the CRTH2 receptor and their use in the treatment of various disorders, including asthma are described.

Modulators of CRTH2 activity

The invention provides variant regulator proteins of secondary metabolite production and nucleic acids encoding said variant regulator proteins. In particular, the invention provides variant regulator molecules of the lovE protein.

love variant regulator molecules

lovE variant regulator molecules

The invention relates to regulators of fungal gene expression and their use in commercial and medical applications. More particularly, the invention relates to regulators of fungal genes involved in production of enzymes, secondary metabolites and other useful products, as well as to regulators of genes involved in fungal invasion. The invention provides novel regulators of fungal gene expression, and methods for using regulator genes in commercial and medical applications.

Isolated nucleic acid molecule encoding a regulator of fungal gene expression

Growing community of inventors

Brookline, MA, United States of America

G Todd Milne